ISRCTN12733334终止2 期
Epidermal growth factor for treatment of non-exudative age-related macular degeneration
fa Eye Research Institute0 个研究点目标入组 7 人开始时间: 2020年5月29日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 7
研究概览
简要总结
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34261661/ (added 16/07/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age of 50 + years
- •2. Pseudophakia
- •3. Presence of geographic atrophy
- •4. Normal intraocular pressure
- •5. Lack of any other ocular disease except for age-related macular degeneration, and absence of any malignancy
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
已完成
2 期
The effectiveness of an epidermal growth factor containing cream on postinflammatory hyperpigmentation after 1064 nm Q-switched Nd:YAG laser treatment of Hori nevus in AsiansPostinflammatory hyperpigmentationParticipants with symmetrical Hori nevusEpidermal growth factor1,064-nm Q-switched Nd:YAG laserHori nevusTCTR20210301001Division of Dermatology Ramathibodi hospital30
已完成
1 期
A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, PaclitaxelLoaded EnGeneIC Delivery Vehicles (Erbitux®EDVsPac) in Patients with Advanced SolidTumoursAdvanced Solid TumoursCancer - Other cancer typesACTRN12609000672257EnGeneIC Pty Ltd32
进行中（未招募）
2 期
THE EFFICACY AND SAFETY OF EPIDERMAL GROWTH FACTOR COMBINED WITH FRACTIONAL CARBON DIOXIDE LASER FOR ACNE SCAR TREATMENT: A SPLIT-FACE TRIAAtrophic acne scarTCTR20201111003Thammasat University23
已完成
2 期
EGFpeeling IAcne scarring, melasm, or other injuries that require chemical peeling.RPCEC00000107Center for Genetic Engineering and Biotechnology (CIGB), in Havana.30
暂停
2 期
Panitumumab as second line therapy for advanced pancreatic ductal adenocarcinoma with wild-type KRAS geneKRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinomaCancer - PancreaticACTRN12617000540314Dr Daniel Croagh24